Clinical Trials
Clinical trials are research studies designed to see if a new treatment is safe and effective. JSG offers clinical trials through our partner, Susquehanna Research Group (SRG).
Clinical Trials Through JSG & SRG
Clinical trials are used to evaluate if a new treatment is more effective and/or has fewer side effects than the standard treatment. Clinical Trials also give patients access to the latest innovations in care. We are excited to offer these opportunities to our qualified patients. You can read more about our sites active clinical trials below and at ClinicalTrials.gov.
Clinical Trials Available at JSG
The trial records located in the National Institute of Health’s U.S. National Library of Medicine include eligibility criteria, the intervention or treatment, completion dates and more information. JSG currently has active clinical trials available to our patients. Learn more about the individual trails below.
ProCares – Clinical Suspicion NOW Re-Opened! »
- This study will enroll individuals 45 years of age or older with clinical suspicion of OR newly diagnosed cancer of the following types of cancer:
- Biliary Tract, Colon, Esophagogastric Junction, Esophagus, Gallbladder, Head and Neck, Liver, Lung, Lymphatic System, Ovary, Pancreas, Rectum, Stomach
- One time blood collection
- No prior cancer history
- Newly diagnosed cancer must be enrolled into the study within 45 days of diagnosis
Caris Biorepository Blood Collection »
Newly Diagnosed Pan-Cancer
- Age 18 and over
- Solid tumor cancer diagnosis within the past 3 months
- No prior cancer history (except non-melanoma skin cancer)
High Risk Genetic Pre-Disposition
- Age 18 and over
- Hereditary diagnosis of one of the following: Breast and Ovarian Cancer Syndrome, Lynch Syndrome, or Li-Fraumeni Syndrome- Must have lab confirmation
- No prior cancer history (except non-melanoma skin cancer)
GSK Balance Study- IBS-D & IBS-M
- Moderate to severe IBS-D or IBS-M according to Rome IV criteria
- Study medication is P2X3 homotrimeric receptor small molecule antagonist that may benefit IBS patients via modulation of neuronal hypersensitivity and potentially intestinal motility- Taken orally twice daily.
- Must be up to date on all CRC screening and/or symptom investigation related to IBS symptoms
- Having abdominal pain at least weekly
- No IBD or Celiac disease
- No bile salt diarrhea
- No recreational marijuana use- medical use is permitted
Janssen UC – Open for Bio Naïve enrollments only
- Age 18 and older
- Moderate to severe UC
- ORAL Anti IL-23
- Prior failure or intolerance of conventional (5-ASA oral corticosteroids, thiopurines) or advanced therapy (biologics or oral advanced therapies) – No failure of 3 or more advanced therapies
- No prior exposure to biologic agent targeting IL-23p19 including guselkumab (Tremfya) mirikizumab (Omvoh), risankizumab (Skyrizi)
- No stoma or ostomy
- Total study length: 52 weeks with additional Open Label Period of 4 years
Janssen CD – Currently Closed for all Cohorts
- Age 18 and older
- Moderate to severe CD
- ORAL Anti IL-23
- Prior failure or intolerance of conventional (oral corticosteroids, thiopurines) or advanced therapy (biologics or oral advanced therapies) ( advanced therapy failure cohort closed as of 26MAR2026)
- No prior exposure to biologic agent targeting IL-23p19 including guselkumab (Tremfya) mirikizumab (Omvoh), risankizumab (Skyrizi)
- No symptomatic strictures
- No extensive colonic resection
- No stoma or ostomy
- Total study length: 52 weeks with additional Open Label Period of 4 years
Sanofi Crohn’s »
- Moderate to severe active Crohn’s
- Unique, first in class, Nanobody therapeutic protein directed at TNF and OX40L (which plays a role in T-helper cell differentiation and maintenance)
- SC injections Q2weeks
- Biologic naïve and failed standard treatment OR failed at least 1 biologic/advanced therapy therapy class but not more than 3
- No fistulizing disease, ostomy or ileoanal pouch or missing more than 2 entire segments of colon
- No opiate use or cannabis use (even if for medical reasons)
- Total study length: 52 weeks with additional Open Label Period of 104 weeks
Sanofi UC »
- Moderate to severe, active UC with rectal bleeding
- Unique, first in class, Nanobody therapeutic protein directed at TNF and OX40L (which plays a role in T-helper cell differentiation and maintenance)
- SC injections Q2weeks
- Biologic naïve and failed standard treatment OR failed at least 1 biologic/advanced therapy class
- No ileal pouch or ostomy
- No diagnosis of inflammatory conditions other than UC (including but not limited to systemic lupus erythematosus, systemic sclerosis, myositis, rheumatoid arthritis, primary biliary cirrhosis, multiple sclerosis, Behcet’s disease, sarcoidosis, etc)
- Total study length: 52 weeks with additional Open Label Period of 104 weeks
T-Scan- UC – Currently Closed for Enrollment »
- Ulcerative colitis- currently symptomatic
- Blood only- one time visit
- Biologic meds are allowed
- NO– drugs that are known to be T cell toxic. The following treatments are not allowed and include:
- Glucocorticoids including prednisone, methylprednisolone (Solumedrol), budesonide (Entocort), hydrocortisone (Solu-cortef), dexamethasone (Decadron), betamethasone (Betaject)
- Sulfasalazine (Azulfidine)
- Aminosalicylates including mesalamine/ mesalazine (Asacol, Pentasa).
- Thiopurines including azathioprine (Imuran) and 6-mercaptopurine (Purixan)
- Systemic JAK inhibitors including tofacitinib (Xeljanz), abrocitinib (Cibinqo), baricitinib (Olumiant), upadacitinib (Rinvoq)
- Methotrexate
CRC or Advanced Adenoma – Exact Sciences »
- Age 18 or older
- Newly diagnosed CRC- not yet treated
- Advanced Adenoma (>1cm remaining and biopsy proven) requiring follow up intervention
C-Diff- Vedanta »
- For patients with C-Diff who have had at least one prior occurrence of C-Diff within the last 6 months
- VE303 is an oral, live biotherapeutic (taken in capsule form x 14 days) that will be administered following completion of a course of standard-of-care (SoC) antibiotics
Crohn’s- Abivax »
- Moderate to severely active Crohn’s disease
- ABX464 is an oral, novel anti-inflammatory drug
- Documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids (CS), immunosuppressants (IS), biologic or biosimilar therapies, or JAK
- Subjects may receive study drug for up to 100 weeks
Celiac – Chugai Daisy Study
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of DONQ52 in Active Treated Celiac Disease
- DONQ52 – a humanized, multispecific IgG1 monoclonal antibody designed to bind HLA-DQ2.5–gluten peptide complexes and block gluten-dependent CD4+ T-cell activation, the initiating step of celiac disease pathology.
- Adult (18–75) with diagnosed celiac disease
- ≥12 months on gluten-free diet
- Ongoing GI symptoms
- Total participation per patient is approximately 54 weeks.
For more info about this study, please visit- https://www.daisycdstudy.com/